Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy.
Roche has opted to withdraw its filing in Europe for a dual regimen for renal cell carcinoma based on checkpoint inhibitor Tecentriq and Avastin, on the grounds that the data supporting it isn’t strong enough.
